Thromb Haemost 2010; 104(04): 831-836
DOI: 10.1160/TH10-02-0093
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients

Explanations and potential ameliorations
Renée A. Douma
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
,
Geerte L. van Sluis
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
,
Pieter W. Kamphuisen
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
,
Maaike Söhne
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
,
Frank W. G. Leebeek
2   Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands
,
Patrick M. M. Bossuyt
3   Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, the Netherlands
,
Harry R. Büller
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
› Author Affiliations
Further Information

Publication History

Received: 04 February 2010

Accepted after major revision: 29 May 2010

Publication Date:
24 November 2017 (online)

Zoom Image

Summary

Patients with malignancy frequently present with clinically suspected pulmonary embolism (PE). However, the safe and efficient combination of a clinical decision rule (CDR) and D-dimer test to rule out PE performs less well in patients with malignancy. We examined potential explanations and analysed whether elevating the D-dimer cut-off could improve the clinical utility. We used data on consecutive patients with suspected PE included in a multicenter management study. The performance of the Wells CDR and the D-dimer test was compared between patients with and without malignancy and multivariable analysis was used to compare the weights of the CDR variables. Furthermore, we combined the CDR (cut-off ≤4) with different D-dimer cut-off levels for the exclusion of PE. Of 3,306 patients with suspected PE, 475 (14%) had cancer. The Wells rule variables were less diagnostic in cancer patients. Increasing the D-dimer cut-off level to 700 μg/l for all ages or using an age-dependent cut-off resulted in an increase in the proportion of patients in whom PE could be excluded from 8.4% to 13% and 12%, respectively. The corresponding false-negative rates were 1.6% (95% confidence interval 0.3–8.7%) and 0.0% (0.0–6.3%). The Wells CDR and D-dimer perform less well in patients with suspected PE if they have cancer. Individual variables in the Wells rule are less diagnostic in cancer patients than in non-cancer patients with suspected PE. A CDR combined with an age-dependent D-dimer cut-off shows a modest improvement of the strategy in cancer patients.